September 28, 2007 – Bristol-Myers Squibb agrees to pay $515 million to settle federal allegations that it illegally marketed Abilify for pediatric use and to treat dementia-related psychosis.
September 28, 2007 – Bristol-Myers Squibb agrees to pay $515 million to settle federal allegations that it illegally marketed Abilify for pediatric use and to treat dementia-related psychosis.